BioSig Technologies Inc () CEO Kenneth Londoner said the medical device company will begin its first-in-human studies at the Mayo Clinic using its PURE EP System at its Jacksonville, Florida hospital.
PURE EP was developed by the Los Angeles based company to improve catheter ablation treatments for heart arrhythmias.
Londoner says the company will approach the commercial market next year.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of BioSig Technologies, Inc. named herein, including the promotion by the Company of BioSig Technologies, Inc. in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE